Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GIPR | P48546 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101508 | 0.91 | GCGR (0.45) | GCGREPHX2TSHRROCK2MCHR1 | |
| SCHEMBL2652649 | 0.87 | GCGR (0.50) | GCGREPHX2KMT2ACYP2D6GIPR | |
| SCHEMBL2650399 | 0.87 | GCGR (0.50) | GCGREPHX2TSHRKMT2ACYP2D6 | |
| SCHEMBL2652582 | 0.87 | GCGR (0.51) | GCGREPHX2KMT2ACYP2D6L3MBTL1 | |
| SCHEMBL6750387 | 0.87 | GCGR (0.50) | GCGREPHX2CYP2D6GIPR | |
| SCHEMBL2651718 | 0.87 | GCGR (0.50) | GCGREPHX2CYP2D6GIPR | |
| SCHEMBL2653146 | 0.87 | GCGR (0.50) | GCGREPHX2KMT2ACYP2D6GIPR | |
| SCHEMBL2651202 | 0.87 | GCGR (0.44) | GCGREPHX2GIPR | |
| SCHEMBL2658771 | 0.86 | GCGR (0.53) | GCGREPHX2CYP2D6GIPR | |
| SCHEMBL2652856 | 0.85 | S1PR3 (0.45) | GCGREPHX2CYP2D6GIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | claimed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | claimed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885EPHX2 2973/4885TSHR 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.